ArticleTherapeutic advances in hematology2022

Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone and carfilzomib-dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis.

Yoshiyuki Onda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.